Two short mitochondrial gene signatures can effectively predict tumor recurrence in larger ER(+) patient populations that received hormonal therapy, as well as in ER(−) patients, and all breast cancers, considered as a single group. The gene discussed is ESR1; the disease is breast carcinoma.